Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 7;15(1):67.
doi: 10.1186/s12955-017-0643-7.

Predictors of quality of life among adolescents and young adults with a bleeding disorder

Affiliations

Predictors of quality of life among adolescents and young adults with a bleeding disorder

John M McLaughlin et al. Health Qual Life Outcomes. .

Abstract

Background: Health-related quality of life (HRQoL) in adolescents and young adults with bleeding disorders is under-researched. We aimed to describe factors related to HRQoL in adolescents and young adults with hemophilia A or B or von Willebrand disease.

Methods: A convenience sample of volunteers aged 13 to 25 years with hemophilia or von Willebrand disease completed a cross-sectional survey that assessed Physical (PCS) and Mental (MCS) Component Summary scores on the SF-36 questionnaire. Quantile regression models were used to assess factors associated with HRQoL.

Results: Of 108 respondents, 79, 7, and 14% had hemophilia A, hemophilia B, and von Willebrand disease, respectively. Most had severe disease (71%), had never developed an inhibitor (65%), and were treated prophylactically (68%). Half of patients were aged 13 to 17 years and most were white (80%) and non-Hispanic (89%). Chronic pain was reported as moderate to severe by 31% of respondents. Median PCS and MCS were 81.3 and 75.5, respectively. Quantile regression showed that the median PCS for women (61% with von Willebrand disease) was 13.1 (95% CI: 2.4, 23.8; p = 0.02) points lower than men. Ever developing an inhibitor (vs never) was associated with a 13.1-point (95% CI: 4.7, 21.5; p < 0.01) PCS reduction. MCS was 10.0 points (95% CI: 0.7, 19.3; p = 0.04) higher for prophylactic infusers versus those using on-demand treatment. Compared with patients with no to mild chronic pain, those with moderate to severe chronic pain had 25.5-point (95% CI: 17.2, 33.8; p < 0.001) and 10.0-point (95% CI: 0.8, 19.2; p = 0.03) reductions in median PCS and MCS, respectively.

Conclusions: Efforts should be made to prevent and manage chronic pain, which was strongly related to physical and mental HRQoL, in adolescents and young adults with hemophilia and von Willebrand disease. Previous research suggests that better clotting factor adherence may be associated with less chronic pain.

Keywords: Chronic pain; Hemophilia; Pain management; Patient adherence; Prophylaxis; von Willebrand disease.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of SF-36 Physical Component Summary scores (n = 108). SF-36, 36-Item Short Form Health Survey; PCS, Physical Component Summary
Fig. 2
Fig. 2
Distribution of SF-36 Mental Component Summary scores (n = 108). SF-36, 36-Item Short Form Health Survey; MCS, Mental Component Summary
Fig. 3
Fig. 3
Box plots for SF-36 component and subscale scores (n = 108). The solid white line represents median value, and the white diamond represents the mean value. PCS, Physical Component Summary score; MCS, Mental Component Summary; BP, bodily pain; PF, physical function; RP, role limitations due to physical health problems; GH, general health; VT, vitality; SF, social functioning; RE, role limitations due to emotional problems; MH, emotional well-being/mental health

Similar articles

Cited by

References

    1. Escobar MA. Advances in the treatment of inherited coagulation disorders. Haemophilia. 2013;19(5):648–59. doi: 10.1111/hae.12137. - DOI - PubMed
    1. Kaufman RJ, Powell JS. Molecular approaches for improved clotting factors for hemophilia. Blood. 2013;122(22):3568–74. doi: 10.1182/blood-2013-07-498261. - DOI - PMC - PubMed
    1. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia a. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J Med. 1993;328(7):453–9. doi: 10.1056/NEJM199302183280701. - DOI - PubMed
    1. Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol. 2008;140(5):479–87. doi: 10.1111/j.1365-2141.2007.06942.x. - DOI - PMC - PubMed
    1. Franchini M, Mengoli C, Lippi G, Targher G, Montagnana M, Salvagno GL, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis. Haemophilia. 2008;14(5):903–12. doi: 10.1111/j.1365-2516.2008.01839.x. - DOI - PubMed